Literature DB >> 21933873

Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide.

Anatoly Slepenkin1, Hencelyn Chu, Mikael Elofsson, Pia Keyser, Ellena M Peterson.   

Abstract

The salicylidene acylhydrazide INP0341 inhibits growth of Chlamydia in HeLa cells, has negligible cell toxicity, and does not inhibit the growth of lactobacilli. The antichlamydial activity of INP0341 was retained when tested in vaginal and semen simulants. Vaginal tissue from INP0341-treated mice appeared similar to control sham-treated mice. To determine whether INP0341 can protect mice from a vaginal challenge, C3H/HeJ mice were either sham or INP0341 treated intravaginally pre- and postinoculation with 5 × 10(2) inclusion-forming units (IFUs) of Chlamydia trachomatis serovar D. Vaginal cultures taken over a month-long period showed a significant difference in the number of control mice that were culture positive versus the number in the INP0341-treated group, 100% (25/25) and 31% (8/26), respectively (P < .05). The quantity of IFUs shed and antibody titers to Chlamydia were significantly higher for the control group (P < .05). In summary, INP0341 is a promising compound to be considered for formulation as a vaginal microbicide.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21933873      PMCID: PMC3182314          DOI: 10.1093/infdis/jir552

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

1.  Topical microbicides for disease prevention: status and challenges.

Authors:  Polly F Harrison; Zeda Rosenberg; Jana Bowcut
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

2.  Opposing selective forces for expression of the gonococcal lactoferrin receptor.

Authors:  James E Anderson; Marcia M Hobbs; Gour D Biswas; P Frederick Sparling
Journal:  Mol Microbiol       Date:  2003-06       Impact factor: 3.501

Review 3.  Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora.

Authors:  V Redondo-Lopez; R L Cook; J D Sobel
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

4.  Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides.

Authors:  P Greenhead; P Hayes; P S Watts; K G Laing; G E Griffin; R J Shattock
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis.

Authors:  D A Eschenbach; P R Davick; B L Williams; S J Klebanoff; K Young-Smith; C M Critchlow; K K Holmes
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

6.  Targeting bacterial virulence: inhibitors of type III secretion in Yersinia.

Authors:  Anna M Kauppi; Roland Nordfelth; Hanna Uvell; Hans Wolf-Watz; Mikael Elofsson
Journal:  Chem Biol       Date:  2003-03

7.  Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity.

Authors:  E M Peterson; G M Zhong; E Carlson; L M de la Maza
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

8.  Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge.

Authors:  Sukumar Pal; Catherine J Luke; Alan G Barbour; Ellena M Peterson; Luis M de la Maza
Journal:  Vaccine       Date:  2003-03-28       Impact factor: 3.641

Review 9.  Bacteriology of the vagina.

Authors:  G B Hill; D A Eschenbach; K K Holmes
Journal:  Scand J Urol Nephrol Suppl       Date:  1984

10.  The association between lymphogranuloma venereum and HIV among men who have sex with men: systematic review and meta-analysis.

Authors:  Minttu M Rönn; Helen Ward
Journal:  BMC Infect Dis       Date:  2011-03-18       Impact factor: 3.090

View more
  22 in total

1.  N-acylated derivatives of sulfamethoxazole and sulfafurazole inhibit intracellular growth of Chlamydia trachomatis.

Authors:  Sania Marwaha; Hanna Uvell; Olli Salin; Anders E G Lindgren; Jim Silver; Mikael Elofsson; Asa Gylfe
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

Review 2.  Chemical inhibitors of the type three secretion system: disarming bacterial pathogens.

Authors:  Miles C Duncan; Roger G Linington; Victoria Auerbuch
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

3.  In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds.

Authors:  Donald N Forthal; Tran B Phan; Anatoly V Slepenkin; Gary Landucci; Hencelyn Chu; Mikael Elofsson; Ellena Peterson
Journal:  Int J Antimicrob Agents       Date:  2012-07-20       Impact factor: 5.283

4.  Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.

Authors:  Bryan J Berube; Katherine R Murphy; Matthew C Torhan; Nicholas O Bowlin; John D Williams; Terry L Bowlin; Donald T Moir; Alan R Hauser
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 5.  Targeting virulence not viability in the search for future antibacterials.

Authors:  Begoña Heras; Martin J Scanlon; Jennifer L Martin
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

6.  The bacterial type III secretion system as a target for developing new antibiotics.

Authors:  Andrew C McShan; Roberto N De Guzman
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

7.  Mutations in hemG mediate resistance to salicylidene acylhydrazides, demonstrating a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity.

Authors:  Patrik Engström; Bidong D Nguyen; Johan Normark; Ingela Nilsson; Robert J Bastidas; Asa Gylfe; Mikael Elofsson; Kenneth A Fields; Raphael H Valdivia; Hans Wolf-Watz; Sven Bergström
Journal:  J Bacteriol       Date:  2013-07-12       Impact factor: 3.490

8.  Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium.

Authors:  Jianfang Li; Chao Lv; Weiyang Sun; Zhenyu Li; Xiaowei Han; Yaoyao Li; Yuemao Shen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

Review 9.  Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target.

Authors:  Alyssa C Fasciano; Lamyaa Shaban; Joan Mecsas
Journal:  EcoSal Plus       Date:  2019-02

10.  A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones suppresses Salmonella infection in vivo.

Authors:  Ludmila N Nesterenko; Nailya A Zigangirova; Egor S Zayakin; Sergey I Luyksaar; Natalie V Kobets; Denis V Balunets; Ludmila A Shabalina; Tatiana N Bolshakova; Olga Y Dobrynina; Alexander L Gintsburg
Journal:  J Antibiot (Tokyo)       Date:  2016-01-06       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.